Canaccord downgrades Intercept, lauds Alfasigma deal as “optimal outcome” (ICPT)


Intercept Pharmaceuticals, a biotech company listed on NASDAQ under the ticker symbol ICPT, has been downgraded to a hold rating by Canaccord Genuity. This downgrade comes after Intercept announced its agreement to be acquired by Alfasigma for $19 per share in cash. Canaccord believes that this deal is the best possible outcome for Intercept, as its drug obeticholic is no longer being pursued as a treatment for NASH (nonalcoholic steatohepatitis) and Oclavia, another drug in its portfolio, potentially faces strong competition in the near future.

Canaccord described the acquisition as a win-win situation for both Intercept and its investors. The $19 per share price offered by Alfasigma is only slightly below Canaccord’s 12-month price target of $20, leading the company to reduce its rating to hold. Canaccord now has a price target of $19 for Intercept.

Overall, the downgrade reflects Canaccord’s view that the acquisition by Alfasigma presents the best outcome for Intercept given the challenges it faces with its drug development pipeline.

Source link

Share post:




More like this

Waterfront Restoration’s Expert Aquatic Weed Removal in Long Lake, MN

Frustrated by the weeds and invasive species preventing his...

Leading-edge Irrigation Maintenance Services in Port Charlotte, FL by Shaffer’s Irrigation

Boosting the health of your landscape through efficient irrigation...

Experience Remarkable Terrazzo Refurbishing in Sarasota, FL with Intra State Terrazzo and Concrete

Keen on understanding the intricacies that underline the worth...